Search clinical trials for: 2B3-101

Total 7278 results

PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia
Cardix Therapeutics LLC

Not yet recruiting

An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia

Bradycardia
Autotelicbio

Recruiting

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

Diabetes Mellitus, Type 2 | Essential Hypertension

Korea, Republic of
BBB-Therapeutics B.V.

Completed

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

Melanoma | Breast Cancer | Lung Cancer | Malignant Glioma | Brain Metastases

United States, Netherlands, France, Belgium
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Apollomics Inc.

Recruiting

APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)

Gastric Cancer | Pancreatic Cancer | NSCLC | Lung Cancer | Brain Tumor | Glioblastoma Multiforme | Advanced Cancer | Colon Cancer | Solid Tumors | Thyroid Cancer | Renal Cancer | Gastroesophageal Junction Adenocarcinoma | EGFR Gene Mutation | MET Amplification | HGF | MET Alteration | MET Fusion | Exon 14 Skipping

United States, Spain, France, United Kingdom, Taiwan, Australia, Finland, Italy, Singapore, Hungary, Canada, Puerto Rico, Russian Federation
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
Brainvectis, a subsidiary of Asklepios BioPharmaceutical...

Active, not recruiting

A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

Huntington Disease

France
Gilead Sciences

Terminated

Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Indolent Non-Hodgkin's Lymphoma

United States
Autotelicbio

Completed

Clinical Trial to Compare Pharmacokinetics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012

Healthy Adult Volunteers

Korea, Republic of
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Global Alliance for TB Drug Development

Completed

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of TBI-223 in Healthy Adults

Tuberculosis | Tuberculosis, Pulmonary

United States
Apollomics Inc.

Recruiting

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Bioequivalence

New Zealand
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
Bayer

Completed

Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes

Sunscreen Agents

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Colorectal Cancer

Japan
Cryonove Pharma
CEISO; Dermatech; LTD HEALTH

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots

Lentigo Solar

Georgia
Cryonove Pharma
CEISO; Dermatech; Sefako Makgatho Health Sciences University

Completed

Tolerance and Performance of Cyto-selective Difluoroethane-based Cryotherapy in the Treatment of Brown Spots.

Solar Lentigo | Post-inflammatory Hyperpigmentation | Senile Lentigo

South Africa
Transwell Biotech Co., Ltd.

Completed

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

Diabetic Foot Ulcer

Taiwan
Amytrx Therapeutics, Inc.
Amarex Clinical Research

Completed

Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

United States
The Netherlands Cancer Institute

Unknown

Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases

Meningeal Carcinomatosis

Netherlands
Alaunos Therapeutics

Completed

Study of ZIO-101 in Multiple Myeloma

Multiple Myeloma

United States, Canada
Alaunos Therapeutics

Completed

A Phase I Trial of ZIO-101 in Hematologic Cancers

Lymphoma | Multiple Myeloma | Acute Leukemia | Chronic Myeloproliferative Disease | Chronic Lymphoproliferative Disease | Poor-risk Myelodysplasia (MDS)

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
Brigham and Women's Hospital

Recruiting

CP101 for the Treatment of Ulcerative Colitis

Ulcerative Colitis

United States
Alaunos Therapeutics

Completed

A Phase I Trial of ZIO-101 in Solid Tumors

Solid Tumors

United States
Aclaris Therapeutics, Inc.

Completed

Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis

Seborrheic Keratosis (SK)

United States
Ralexar Therapeutics, Inc.

Completed

A Study in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis | Eczema, Atopic

United States
Scioderm, Inc.
Amicus Therapeutics

Completed

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

Epidermolysis Bullosa

United States
Azure Biotech Inc.

Not yet recruiting

Open-Label Study of Vaginal AZU-101 in Postmenopausal Women

Postmenopausal Symptoms
Abalonex, LLC

Not yet recruiting

Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury

Traumatic Brain Injury | Cerebral Edema
Benjamin Izar

Terminated

ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma (ATX-101)

Leiomyosarcoma | Liposarcoma

United States
Flame Biosciences

Completed

A Bioavailability Study of FL-101 in Healthy Male and Female Subjects

Healthy Subjects

United States
Gilead Sciences

Withdrawn

A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Bioavailability of IV and SC LBR-101

Bioavailability and Pharmacokinetics

United States
Sen-Jam Pharmaceutical

Completed

Safety and Efficacy of a Combination Product for the Prevention of Veisalgia

Veisalgia
Alaunos Therapeutics

Unknown

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

Advanced Solid Tumors | Lymphomas

Canada
Alaunos Therapeutics

Unknown

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Advanced Cancer

United States
BlueWillow Biologics
Porton Biopharma Ltd.

Completed

A Safety and Immunogenicity of Intranasal Nanoemulsion Adjuvanted Recombinant Anthrax Vaccine in Healthy Adults (IN NE-rPA)

Anthrax

United States
Desentum Oy

Completed

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Birch Pollen Allergy

Finland
Healthpoint

Withdrawn

HP011-101, HP828-101, and Standard Care for Pressure Ulcers

Pressure Ulcers
Gilead Sciences

Completed

Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber

Allergic Rhinitis

Austria
Lantheus Medical Imaging

Completed

A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure

Heart Failure

United States
Ralexar Therapeutics, Inc.

Unknown

Study in Subjects With Moderate Atopic Dermatitis

Atopic Dermatitis Eczema

United States, Canada
Axovant Sciences Ltd.

Terminated

Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
Gilead Sciences

Terminated

An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States
Axovant Sciences Ltd.

Completed

Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

Dementia With Lewy Bodies

United States, Canada, France, Italy, Netherlands, Spain, United Kingdom
Santen Inc.

Completed

Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients

Dry Eye

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Recurrent Chronic Lymphocytic Leukemia

United States

Search clinical trials for: 2B3-101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Dominican Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations